Back to Search
Start Over
GSK announces Blenrep combo reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory MM
- Source :
- PharmaBiz. June 4, 2024
- Publication Year :
- 2024
-
Abstract
- GSK plc announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.796300201